COVID-19 highlights the acute need for non-invasive, point-of-care, remote monitoring

hemodynamic measurement solutions. Find out how CPS meets the need.

Sensydia in the news

June 10, 2025

Sensydia Awarded Second Phase of $3M NIH Grant to Advance CPS™ Clinical Utility

The NIH has activated Phase II funding of Sensydia’s Fast-Track STTR grant to support real-world clinical utility studies of the Cardiac Performance System (CPS™). This non-dilutive funding marks a key milestone as the company continues to validate CPS for patients with heart failure and pulmonary hypertension.

Learn More

Sensydia Awarded Second Phase of $3M NIH Grant Award to Demonstrate Clinical Utility of Cardiac Performance System (CPS™)

Rusty Page appointed President and Chief Operating Officer of Sensydia.

Sensydia Appoints Rusty Page as President and Chief Operating Officer to Support Growth and Commercialization of the Cardiac Performance System (CPS™)

Sensydia’s Cardiac Performance System (CPS™) is designed for fast, safe, and non-invasive cardiac performance assessment that can be performed almost anywhere, avoiding the need to visit a catheterization lab. Source: Sensydia.

Sensydia in the news

Sensydia Awarded Second Phase of $3M NIH Grant to Advance CPS™ Clinical Utility

Sensydia Awarded Second Phase of $3M NIH Grant Award to Demonstrate Clinical Utility of Cardiac Performance System (CPS™)

Sensydia Appoints Rusty Page as President and Chief Operating Officer to Support Growth and Commercialization of the Cardiac Performance System (CPS™)

Sensydia Announces First Patient Enrolled in Pivotal Study of Non-Invasive Cardiac Performance System (CPS™)

Clinical data presented at ACC 2025 shows Sensydia CPS™ provides accurate assessment of mean pulmonary artery pressure non-invasively

Sensydia Completes Fifth Study for Heart-Sound AI

Sensydia secures $3M NIH grant to advance AI-based cardiac assessment platform